Your browser doesn't support javascript.
loading
Revisiting the non-Gaucher-GBA-E326K carrier state: Is it sufficient to increase Parkinson's disease risk?
Goldstein, Orly; Gana-Weisz, Mali; Cohen-Avinoam, Danielle; Shiner, Tamara; Thaler, Avner; Cedarbaum, Jesse M; John, Sally; Lalioti, Maria; Gurevich, Tanya; Bar-Shira, Anat; Mirelman, Anat; Giladi, Nir; Orr-Urtreger, Avi.
  • Goldstein O; The Genomic Research Laboratory for Neurodegeneration, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
  • Gana-Weisz M; The Genomic Research Laboratory for Neurodegeneration, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
  • Cohen-Avinoam D; The Genomic Research Laboratory for Neurodegeneration, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
  • Shiner T; Laboratory for Early Markers of Neurodegeneration, Center for the study of Movement, Cognition and Mobility, Neurological Institute, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Sackler Faculty of Medicine, Sagol School of Neuroscience, Tel Aviv University, Israel.
  • Thaler A; Laboratory for Early Markers of Neurodegeneration, Center for the study of Movement, Cognition and Mobility, Neurological Institute, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Sackler Faculty of Medicine, Sagol School of Neuroscience, Tel Aviv University, Israel.
  • Cedarbaum JM; Biogen, Inc, Cambridge, MA, USA; Coeruleus Clinical Sciences LLC, Woodbridge, CT, USA.
  • John S; Biogen, Inc, Cambridge, MA, USA.
  • Lalioti M; Biogen, Inc, Cambridge, MA, USA.
  • Gurevich T; Laboratory for Early Markers of Neurodegeneration, Center for the study of Movement, Cognition and Mobility, Neurological Institute, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Sackler Faculty of Medicine, Sagol School of Neuroscience, Tel Aviv University, Israel.
  • Bar-Shira A; The Genomic Research Laboratory for Neurodegeneration, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
  • Mirelman A; Laboratory for Early Markers of Neurodegeneration, Center for the study of Movement, Cognition and Mobility, Neurological Institute, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Sackler Faculty of Medicine, Sagol School of Neuroscience, Tel Aviv University, Israel.
  • Giladi N; Laboratory for Early Markers of Neurodegeneration, Center for the study of Movement, Cognition and Mobility, Neurological Institute, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Sackler Faculty of Medicine, Sagol School of Neuroscience, Tel Aviv University, Israel.
  • Orr-Urtreger A; The Genomic Research Laboratory for Neurodegeneration, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Sackler Faculty of Medicine, Sagol School of Neuroscience, Tel Aviv University, Israel. Electronic address: aviorr@tasmc.health.gov.il.
Mol Genet Metab ; 128(4): 470-475, 2019 12.
Article en En | MEDLINE | ID: mdl-31662221
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Enfermedad de Parkinson / Sustitución de Aminoácidos / Predisposición Genética a la Enfermedad / Alelos / Glucosilceramidasa Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Male Idioma: En Año: 2019 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Enfermedad de Parkinson / Sustitución de Aminoácidos / Predisposición Genética a la Enfermedad / Alelos / Glucosilceramidasa Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Male Idioma: En Año: 2019 Tipo del documento: Article